.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Queensland Health
Teva
QuintilesIMS
Boehringer Ingelheim
Cerilliant
UBS
Chubb
Healthtrust
Moodys

Generated: November 18, 2017

DrugPatentWatch Database Preview

Vicuron Company Profile

« Back to Dashboard

What is the competitive landscape for VICURON, and what generic alternatives to VICURON drugs are available?

VICURON has one approved drug.

There are three US patents protecting VICURON drugs.

There are sixty-four patent family members on VICURON drugs in twenty-nine countries and eight supplementary protection certificates in seven countries.

Summary for Vicuron

International Patents:64
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-001Feb 17, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-002Nov 14, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-001Feb 17, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-002Nov 14, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-002Nov 14, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-001Feb 17, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Vicuron

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-002Nov 14, 2006► Subscribe► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-001Feb 17, 2006► Subscribe► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-002Nov 14, 2006► Subscribe► Subscribe
Vicuron
ERAXIS
anidulafungin
INJECTABLE;IV (INFUSION)021632-001Feb 17, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Vicuron

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,932,543 Cyclic peptide antifungal agents and process for preparation thereof► Subscribe
6,916,784 Cyclic peptide antifungal agents and process for preparation thereof► Subscribe
6,743,777 Cyclic peptide antifungal agents and process for preparation thereof► Subscribe
6,384,013 Cyclic peptide antifungal agents and process for preparation thereof► Subscribe
7,790,744Cyclic peptide antifungal agents and process for preparation thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Vicuron Drugs

Country Document Number Estimated Expiration
Czech Republic9300416► Subscribe
Japan4936595► Subscribe
Israel105048► Subscribe
JapanH0656892► Subscribe
Brazil1100417► Subscribe
Germany69331922► Subscribe
Australia3249100► Subscribe
Malaysia136593► Subscribe
Czech Republic288974► Subscribe
Japan3520071► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Vicuron Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008 00017Denmark► Subscribe
C/GB08/016United Kingdom► SubscribePRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920
0334Netherlands► Subscribe300334, 20130318, EXPIRES: 20180317
0561639/01Switzerland► SubscribePRODUCT NAME: ANIDULAFUNGIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58325 03.09.2009
C002/2008Ireland► SubscribeSPC002/2008: 20081105, EXPIRES: 20180317
C0009France► SubscribePRODUCT NAME: ANIDULAFUNGINE; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
406Luxembourg► Subscribe91406, EXPIRES: 20180318
00334Netherlands► SubscribePRODUCT NAME: ANIDULAFUNGIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Accenture
Teva
Queensland Health
Dow
Johnson and Johnson
Harvard Business School
Cipla
Argus Health
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot